Veeco launches Lumina+ MOCVD system, receives Rocket Lab order
Uniqure NV stock reached a significant milestone, hitting a 52-week high of 51.67 USD. The biotechnology company, now valued at $3.2 billion, has caught analysts’ attention with price targets ranging from $27 to $95. This marks a notable achievement for the biotechnology company, reflecting a remarkable 1-year change of 854.77%. According to InvestingPro analysis, while the stock shows strong momentum, technical indicators suggest it’s currently in overbought territory. The surge in stock price underscores investor confidence and interest in Uniqure’s potential and performance in the gene therapy sector. This 52-week high comes amid a broader rally in biotech stocks, as advancements in medical technology continue to capture market attention. InvestingPro data reveals the stock is trading above its Fair Value, with 16 additional key insights available to subscribers.
In other recent news, uniQure has seen several updates regarding its AMT-130 treatment for Huntington’s disease. Guggenheim significantly raised its price target for uniQure to $95 from $28, maintaining a Buy rating, citing compelling 36-month data from the treatment. Similarly, Cantor Fitzgerald increased its price target to $80 from $47, while keeping an Overweight rating, and updated the probability-of-success estimates for AMT-130 to 75% in the U.S. and 45% in the EU5 markets. Mizuho also raised its price target to $60 from $30, maintaining an Outperform rating, following positive Phase 1/2 trial results. The data revealed statistically significant results compared to external controls on key endpoints. The updates reflect growing confidence among analysts in the potential success of uniQure’s gene therapy for Huntington’s disease. These developments highlight the company’s progress in advancing its treatment pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.